All In Biotech

Drug Trial Radar · NCT05284617

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

Exploratory Phase 2A, Double-blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety, Tolerability, PD, and PK of HU6 for the Treatment of Subjects With Obese Heart Failure With Preserved Ejection Fraction (HFpEF)

Last checked: Nov 19, 2026Latest source record: Aug 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

67

Actual

Start

Oct 30, 2022

Primary completion

May 24, 2024

Study completion May 30, 2024

Sponsor

Lead sponsor
Rivus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Mar 17, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2A, randomized, parallel-group, placebo-controlled, double-blind, within subject dose escalation trial with 3 dose levels of HU6 and placebo. Subjects will be randomized (1:1) either to HU6 or placebo. Two dose levels will be administered in sequential order (150 mg daily followed by 300 mg daily), each for 20 days, to reach the third and highest dose of 450 mg daily if safety and tolerability are demonstrated at the lower 2 preceding doses. Administration of the 450 mg high dose will continue for a total of 94 days, with a safety follow-up visit within \~14 days of the last dose.

Conditions

  • Heart Failure With Preserved Ejection Fraction

Interventions

  • HU6Drug

    HU6 is being evaluated for its efficacy in improving cardiovascular function in obese subjects with HF with preserved ejection fraction (HFpEF).

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate weight reduction while on HU6 treatmentTime frame: 5 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • National Heart Institute

    Beverly Hills, California

  • Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center

    Torrance, California

  • New Generation of Medical Research

    Hialeah, Florida

  • Broward Research Center

    Pembroke Pines, Florida

  • Northwestern University

    Chicago, Illinois

  • The University of Chicago Medical Center

    Chicago, Illinois

  • Johns Hopkins University

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Saint Luke's Mid America Heart Institute

    Kansas City, Missouri

  • Weill Cornell Medicine

    New York, New York

  • Wake Forest

    Winston-Salem, North Carolina

  • The Lindner Center for Research and Education at The Christ Hospital

    Cincinnati, Ohio

  • Medical University of South Carolina

    Charleston, South Carolina

  • University of Texas Southwestern

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.